NIKTIMVO: payments to doctors
Payments that named NIKTIMVO as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.1M
- Providers
- 2,380
- Transactions
- 4,214
- Average per transaction
- $266
The per-transaction average — $266 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 2,380 providers the average total is $471, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Incyte Corporation | $1,113,403 | 99.3% |
| Syndax Pharmaceuticals, Inc. | $7,342 | 0.7% |